Role of statin therapy in the coronary bypass patient.
Statins have been proven to prevent or delay ischemic events in patients at risk for atherosclerotic coronary disease. Increasing evidence suggests that statin therapy is also beneficial to patients undergoing coronary revascularization. In this review statin therapy will be shown to improve vein graft patency, minimize recurrent ischemic events, and decrease the need for repeat revascularization procedures in patients who have undergone coronary artery bypass grafting.
Lazar
Harold L
HL
Department of Cardiothoracic Surgery, Boston University School of Medicine and the Boston Medical Center, 88 E. Newton Street, B404, Boston, MA 02118, USA. harold.lazar@bmc.org
D000208:Acute Disease; D000328:Adult; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D023903:Coronary Restenosis / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy; D010819:Physician's Role; D011183:Postoperative Complications / Q000517:prevention & control; D020521:Stroke / Q000517:prevention & control
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors